| | Advanced Search

 

Paul Giorgio: Elizabeth Warren is Right on Student Loans—MINDSETTER Paul Giorgio examines the student debt crisis

Central MA College Standout: Smith College’s Megan Baker—Spotlight on a bright student...

Organize + Energize: 7 Reasons to Hire a Professional Organizer—With a little help from your friends...

Rob Horowitz: The Civil Rights Act, 50 Years Later—Celebrating a milestone...

RE/MAX Reports 36.3% Increase in Pending MA Home Sales for March—Leading the region in pending home sales

College Admissions: 8 Ways Teens Can Explore Careers This Summer—Summer is the perfect time for students to…

Revs Return Home, Pick Up Crucial Win—The 2014 season had not started the way…

Monfredo: Worcester’s ‘City that Reads’ Book Drive Needs Your Help—Reading is a right, not a privilege

QCC 50th, Celebrating Students: Kimberly Lawrence—A QCC graduate making a difference

Fit for Life: Success Starts with Getting on the Right Path—Which direction are you headed?

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.

Comments:

Nancy Thomas

Where does this money get applied?




Write your comment...

You must be logged in to post comments.